UMINESCE: Phase 3 study of satralizumab, a therapeutic recycling antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis

被引：0

作者：

Kaminski, H. ^{[1
]}

Zhao, C. ^{[2
]}

zu Horste, G. Meyer ^{[3
]}

O'Connor, K. ^{[4
]}

Klingelschmitt, G. ^{[5
]}

Krumova, P. ^{[5
]}

Bolt, S. ^{[6
]}

Vodopivec, I. ^{[5
]}

Murai, H. ^{[7
]}

机构：

[1] George Washington Univ, Washington, DC USA

[2] Fudan Univ, Shanghai, Peoples R China

[3] Univ Munster, Munster, Germany

[4] Yale Univ, New Haven, CT USA

[5] F Hoffmann La Roche Ltd, Basel, Switzerland

[6] Roche Prod, Welwyn Garden City, Herts, England

[7] Univ Hlth & Welf, Narita, Japan

来源：

NEUROMUSCULAR DISORDERS | 2022年 / 32卷

关键词：

D O I：

10.1016/j.nmd.2022.07.162

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P.92

引用

页码：S80 / S81

页数：2

共 50 条

[21] A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as monotherapy for patients with neuromyelitis optica spectrum disorder (NMOSD)
Traboulsee, A.
Greenberg, B.
Bennett, J. L.
Szczechowski, L.
Fox, E.
Shkrobot, S.
Yamamura, T.
Terada, Y.
Kawata, Y.
Melia, A.
Gianella-Borradori, A.
Weinshenker, B. G.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 730 - 731
[22] A SOLID-PHASE ENZYME-IMMUNOASSAY FOR ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY IN MYASTHENIA-GRAVIS PATIENTS
KOBAYASHI, N
SUGITA, H
TERADA, E
GHODA, A
OKUDAIRA, H
OGITA, T
MIYAMOTO, T
JOURNAL OF IMMUNOLOGICAL METHODS, 1984, 73 (02) : 267 - 272
[23] Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
Bril, Vera
Druzdz, Artur
Grosskreutz, Julian
Habib, Ali A.
Mantegazza, Renato
Sacconi, Sabrina
Utsugisawa, Kimiaki
Vissing, John
Vu, Tuan
Boehnlein, Marion
Bozorg, Ali
Gayfieva, Maryam
Greve, Bernhard
Woltering, Franz
Kaminski, Henry J.
LANCET NEUROLOGY, 2023, 22 (05): : 383 - 394
[24] Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
Howard, James F., Jr.
Utsugisawa, Kimiaki
Benatar, Michael
Murai, Hiroyuki
Barohn, Richard J.
Illa, Isabel
Jacob, Saiju
Vissing, John
Burns, Ted M.
Kissel, John T.
Muppidi, Srikanth
Nowak, Richard J.
O'Brien, Fanny
Wang, Jing-Jing
Mantegazza, Renato
Mazia, Claudio Gabriel
Wilken, Miguel
Ortea, Carolina
Saba, Juliet
Rugiero, Marcelo
Bettini, Mariela
Vidal, Gonzalo
Garcia, Alejandra Dalila
Lamont, Phillipa
Leong, Wai-Kuen
Boterhoven, Heidi
Fyfe, Beverly
Roberts, Leslie
Jasinarachchi, Mahi
Willlems, Natasha
Wanschitz, Julia
Loscher, Wolfgang
De Bleecker, Jan
Van den Abeele, Guy
de Koning, Kathy
De Mey, Katrien
Mercelis, Rudy
Wagemaekers, Linda
Mahieu, Delphine
Van Damme, Philip
Smetcoren, Charlotte
Stevens, Olivier
Verjans, Sarah
D'Hondt, Ann
Tilkin, Petra
Alves de Siqueira Carvalho, Alzira
Hasan, Rosa
Brockhausen, Igor Dias
Feder, David
Ambrosio, Daniel
LANCET NEUROLOGY, 2017, 16 (12): : 976 - 986
[25] Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
Nishimoto, Norihiro
Terao, Kimio
Mima, Toru
Nakahara, Hideko
Takagi, Nobuhiro
Kakehi, Takahiro
BLOOD, 2008, 112 (10) : 3959 - 3964
[26] Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: Phase 3 adapt study results
Mantegazza, Renato
Bril, Vera
Vu, Tuan
Karam, Chafic
Peric, Stojan
Margania, Temur
Murai, Hiroyuki
Bilinska, Malgorzata
Shakarishvili, Roman
Smilowski, Marek
Guglietta, Antonio
Ulrichts, Peter
Vangeneugden, Tony
Utsugisawa, Kimiaki
Verschuuren, Jan
Howard, James
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
[27] Response to rozanolixizumab in patients with generalized myasthenia gravis (gMG) from the Phase 3 MycarinG study
Vissing, J.
Druzdz, A.
Grosskreutz, J.
Habib, A.
Mantegazza, R.
Utsugisawa, K.
Vu, T.
Grimson, F.
Lejdstrom, R. Beau
Pulido-Valdeolivas, I.
Tarancon, T.
Bril, V.
NEUROMUSCULAR DISORDERS, 2023, 33 : S178 - S179
[28] Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: phase 3 adapt study results
Mantegazza, R.
Bril, V.
Vu, T.
Karam, C.
Peric, S.
Margania, T.
Murai, H.
Biliska, M.
Shakarishvili, R.
Smilowski, M.
Guglietta, A.
Ulrichts, P.
Vangeneugden, T.
Utsugisawa, K.
Verschuuren, J.
Howard, J.
EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 80 - 80
[29] A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases
Lyman, Michael
Lieuw, Vincent
Richardson, Robyn
Timmer, Anjuli
Stewart, Christine
Granger, Steve
Woods, Richard
Silacci, Michela
Grabulovski, Dragan
Newman, Roland
JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (24) : 9326 - 9334
[30] THE MYASTHENIA GRAVIS INEBILIZUMAB TRIAL (MINT): DESIGN OF RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF AN ANTI-CD19 MONOCLONAL ANTIBODY IN GENERALIZED MYASTHENIA GRAVIS
Nowak, R.
Benatar, M.
Ciafaloni, E.
Howard, J.
Leite, M.
Utsugisawa, K.
Vissing, J.
Wu, Y.
Abuhatzira, L.
Katz, E.
Ratchford, J.
MUSCLE & NERVE, 2020, 62 : S115 - S115

← 1 2 3 4 5 →